CHIRON/PHARMACIA TO DEVELOP HUMAN DISMUTASE SUPEROXIDE
CHIRON/PHARMACIA TO DEVELOP HUMAN DISMUTASE SUPEROXIDE under a 50-50 joint venture agreement announced Sept. 11. "The objective of the joint venture will be the development of human superoxide dismutase (HSOD) to protect tissues from injury either during inflammation or following ischemia," a press release states. Under a preliminary agreement signed Sept. 10, Chiron will provide recombinant technology and related process engineering for the production of HSOD in genetically engineered yeast cells in return for "an initial payment" from Pharmacia. The Uppsala, Sweden-based Pharmacia will contribute its pharmacology data, provide regulatory and other premarketing assistance, and "fund the activities of the joint venture as necessary to secure regulatory approval of HSOD," the release notes. The release adds that Chiron will retain the right to manufacture bulk HSOD for the joint venture products, which will be distributed by Pharmacia's worldwide sales force. Operating out of Chiron's Emeryville, California facilities, the joint venture will perform preclinical testing, human clinicals, and marketing for clinical applications of HSOD products, including organ transplantation and cardiovascular indications, the two firms said. Published experiments using animal models "suggest that HSOD can prevent the oxidative damage and resultant loss of organ supply to tissues previously deprived of circulation," the release states. "Establishment of the joint venture is subject to the negotiation of definitive agreements and the approval of the board of directors of each company," the firms said. Chiron currently has active development agreements with Merck, for a recombinant hepatitis B vaccine now in clinicals; with Nordisk, for recombinant factor VIII and human insulin; with Hoechst, covering rDNA-derived tissue plasminogen activator; and with Ciba-Geigy, for insulin-like growth factors.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth